Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
← catalyst calendarNCT04349436 · readout ≤ 1,077 d
Sponsored by Replimune, Inc. (industry) · REPL — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
69actual
Sites
24
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-05-15 | actual | When the study began enrolling |
| Primary completion | Jul 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2020-04-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Merkel Cell Carcinoma
- Basal Cell Carcinoma
- Locally Advanced Cutaneous Squamous Cell Carcinoma
- Cancer
Intervention
- Biological: RP1, intra-tumoral injection, oncolytic virus
Primary outcomes
what the primary-completion date above is the date OFPrimary Objective for Patients with Locally Advances CSCC (laCSCC)
measured 36 months
Primary Efficacy Objective for Patients with Other Skin Cancers
measured 36 months
Primary Safety Objective for Patients with Other Skin Cancers
measured 36 months
Permalink · REPL's whole pipeline · Catalyst calendar · Every registered study · What changed